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The de novo synthesis of glycerolipids in mammalian cells begins with the acylation of 33 
glycerol-3-phosphate, catalyzed by glycerol-3-phosphate acyltransferase (GPAT). 34 
GPAT2 is a mitochondrial isoform primarily expressed in testis under physiological 35 
conditions.  Because it is aberrantly expressed in multiple myeloma, it has been 36 
proposed as a novel cancer testis gene.  Using a bioinformatics approach, we found 37 
that GPAT2 is highly expressed in melanoma, lung, prostate and breast cancer, and we 38 
validated GPAT2 expression at the protein level in breast cancer by 39 
immunohistochemistry.  In this case GPAT2 expression correlated with a higher 40 
histological grade.  5-Aza-2’deoxycytidine treatment of human cells lines induced 41 
GPAT2 expression suggesting epigenetic regulation of gene expression.  In order to 42 
evaluate the contribution of GPAT2 to the tumor phenotype, we silenced its expression 43 
in MDA-MB-231 cells.  GPAT2 knockdown diminished cell proliferation, anchorage 44 
independent growth, migration and tumorigenicity, and increased staurosporine-induced 45 
apoptosis.  In contrast, GPAT2 over-expression increased cell proliferation rate and 46 
resistance to staurosporine-induced apoptosis. To understand the functional role of 47 
GPAT2, we performed a co-expression analysis in mouse and human testis and found a 48 
significant association with semantic terms involved in cell cycle, DNA integrity 49 
maintenance, piRNA biogenesis and epigenetic regulation.  Overall, these results 50 
indicate the GPAT2 would be directly associated with the control of cell proliferation. In 51 
conclusion, we confirm GPAT2 as a cancer testis gene and that its expression 52 
contributes to the tumor phenotype of MDA-MB-231 cells. 53 
 54 
INTRODUCTION 55 
The de novo synthesis of glycerolipids in mammalian cells begins with the acylation 56 
of glycerol-3-phosphate, catalyzed by glycerol-3-phosphate acyltransferase (GPAT) [1].  57 
As occurs in many other lipid metabolic reactions, several isoforms catalyze this step.  58 
At least four different genes encode for GPAT isoforms 1-4, which differ in tissue 59 
expression pattern, subcellular localization, fatty acyl-CoA substrate preference, and 60 
sensitivity to N-ethylmaleimide.  GPAT1 and GPAT2 are mitochondrial isoforms, 61 
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whereas GPAT3 and GPAT4 are localized in the endoplasmic reticulum [2].  While 62 
GPAT1, GPAT3 and GPAT4 are expressed in lipogenic tissues and their activities are 63 
associated with triacylglycerol and phospholipid synthesis, the expression pattern of 64 
GPAT2 is more prominent in testis [3].  GPAT2, which is expressed in the germ line 65 
cells in mouse and rat testis, is highly selective for arachidonoyl-CoA as a substrate [4].  66 
The Gpat2 gene is transcribed only in primary spermatocytes and the level of both 67 
mRNA and protein decreases in subsequent steps of the spermatogenic cycle.  The 68 
function of GPAT2 in male reproduction remains unknown, but a recent publication 69 
showed that GPAT2 is essential for the biogenesis of piRNA which maintains genome 70 
integrity in germ line cells [5].  71 
Based on a study of multiple myeloma, GPAT2 was proposed to be a novel 72 
“cancer-testis” gene (CT gene) candidate [6].  CT genes encode proteins whose 73 
expression is restricted to male germ cells and to several tumors of different histological 74 
origins, but CT gene products are absent or expressed at a low level in normal somatic 75 
cells [7].  Their expression is usually regulated by epigenetic mechanisms, and they are 76 
immunogenic.  Due to their immunogenic properties, growing lists of CT antigens are 77 
being considered as targets for cancer vaccines [8].  However, little is known about the 78 
function of CT gene products in either spermatogenic or malignant cells.  79 
The aim of this study was to determine whether GPAT2 behaves as a CT gene and 80 
to evaluate the phenotypic consequence of GPAT2 expression in cancer cells.  We 81 
chose the MDA-MB-231 cell line derived from human breast carcinoma because these 82 
cells express high levels of GPAT2.  GPAT2 gene knockdown in this cancer cell model 83 
showed that GPAT2 can promote cell tumorigenicity, proliferation and survival.  84 
 85 
EXPERIMENTAL PROCEDURES 86 
 87 
Ethics Statement- The studies performed with nude mice were approved by the 88 
Directive Board of the INIBIOLP and were carried out in accordance with the AVMA 89 
Animal Welfare Policies (http://www.avma.org/issues/animal_welfare/policies.asp) and 90 
AVMA Guidelines on Euthanasia (http://www.avma.org/issues/ 91 
animal_welfare/euthanasia.pdf). (INIBIOLP’s Animal Welfare Assurance No. A5647–01). 92 
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Cell lines: Human breast adenocarcinoma MDA-MB-231 and colorectal 93 
adenocarcinoma HCT116 cells were purchased from the American Type Culture 94 
Collection [9] (Manassas, VA, USA).  Stable cell lines expressing a small-hairpin RNA 95 
targeting GPAT2 mRNA (shRNA-GPAT2) and a non-silencing scrambled RNA (shRNA-96 
scr) were obtained in our laboratory on the commercial MDA-MB-231 and HCT116 cell 97 
lines using routine techniques as described below.   98 
Bioinformatics analysis- 1. Transcriptional profile of GPAT2 in human normal 99 
tissues and cancer cell lines: to evaluate GPAT2 mRNA expression in human normal 100 
tissues, we analyzed a genome wide gene expression profile of 677 samples 101 
(InSilicoDB, GSE7307).  This data set comprises normal and diseased tissues and cell 102 
lines.  Therefore, samples of diseased tissues and cell lines were excluded from the 103 
analysis.  In addition, to obtain a more general representation of the different tissues, 104 
we combined those samples corresponding to different locations of the encephalon 105 
(thalamus, midbrain, caudate, etc.) under the single category designated as “brain.”  We 106 
also consolidated samples with synonymous names, such as breast and mammary 107 
gland and omitted tissues represented by just a single sample.  A filtered dataset of 36 108 
normal human tissues was used. 109 
In the search for an in vitro model in which to study the role of GPAT2 in cancerous 110 
cells, we assessed the mRNA expression of GPAT2 in a dataset of 174 samples from 111 
59 cell lines from 9 different cancer tissues. (InSIlicoDB, GSE32474)  112 
2. Transcriptional profile of GPAT2 across human tumor samples: to perform a 113 
comparative analysis of GPAT2 mRNA expression in different human cancers, we 114 
combined ten independent oligo-microarray studies available in a public database.  To 115 
generate a homogeneous dataset, the frozen robust multiarray analysis (fRMA) 116 
preprocessed expression matrixes of the studies GSE37642 (Acute myeloid leukemia, 117 
AML), GSE7553 (primary melanoma, metastatic melanoma, squamous and basal cell 118 
carcinomas), GSE31684 (bladder carcinoma), GSE9843 (hepatocellular carcinoma), 119 
GSE18842 (lung cancer), GSE14333 (colorectal cancer), GSE21653 (breast cancer), 120 
GSE20685 (breast cancer), GSE17591 (prostate cancer), and GSE39671 (chronic 121 
lymphocytic leukemia, CLL) were downloaded from the InSilico database 122 
(http://insilico.ulb.ac.be/) [10].  These gene expression profiles were all developed with 123 
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the Affymetrix HG U133 Plus2 platform (GPL570).  Only tumor samples were 124 
considered and control and/or normal samples present in some datasets were 125 
excluded.  The frozen Robust Multiarray Analysis (fRMA) pre-processing algorithm 126 
allows analysis of independent oligo-microarray studies/batches, and then combines the 127 
data for further statistical analysis [11].  Our final compiled gene expression data were 128 
1693 cancer samples.  Expression values for GPAT2 were ordered increasingly, and 129 
divided into 3-quantile distribution, identifying three groups in terms of expression levels: 130 
low, moderate and high. Quantiles are points taken at regular intervals from the 131 
cumulative distribution function of a random variable. The 3-quantiles are called terciles. 132 
In this way, one-third of all the ranked observations are smaller than the first tercile (this 133 
category was termed low), one-third lie between the first and second tercile (this 134 
category was termed moderate), and one-third are larger than the second tercile (this 135 
category was termed high). 136 
3. GPAT2 co-expression analysis in testis: to further analyze functional pathways 137 
associated with GPAT2, we employed the ‘Guilt by association’ principle, which states 138 
that gene co-expression might indicate shared regulatory mechanisms and roles in 139 
related biological processes [12].  Because GPAT2 resides principally in testis tissue, 140 
co-expressed genes in mouse and human testis were obtained by using the web-based 141 
bioinformatics tool Multiexperiment Matrix (MEM) http://biit.cs.ut.ee/mem/ [13].  We 142 
selected the 300-best positively correlated genes (p<0.0001) and performed the 143 
functional enrichment analysis using the DAVID [14] and REVIGO [15] tools. 144 
 145 
Cell lines and culture conditions-  The human MDA-MB-231, HeLa, HEK293, MCF7 146 
and HCT116 cell lines, derived from mammary adenocarcinoma, cervix 147 
adenocarcinoma, embryonic kidney and colorectal adenocarcinoma, respectively, and 148 
the normal monkey kidney Vero cell line were purchased from ATCC and maintained in 149 
DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 150 





GPAT2 silencing-  For human GPAT2 silencing, MDA-MB-231 and HCT116 cells 154 
were transfected using Lipofectamine 2000 Reagent (Life Technologies) with HuSH-29 155 
plasmid (OriGene) coding for shRNA against human GPAT2 mRNA, and selected for 156 
puromycin resistance to generate the respective shRNA-GPAT2 cell line.  A non-157 
effective scrambled sequence shRNA plasmid was used to create a negative control for 158 
each cell line (shRNA-Scr).  Both plasmids also contain a sequence coding for green 159 
fluorescent protein driven by a CMV promoter.  GPAT2 knock down was assessed by 160 
QPCR. 161 
 162 
Quantitative Real-time PCR- Total RNA was isolated from cell lines using TRIZOL 163 
(Life Technologies) following the manufacturer’s instructions, and 1 µg RNA was used 164 
for cDNA synthesis employing High Capacity Reverse Transcription Kit (Applied 165 
Biosystems).  A 1/10 cDNA dilution was used for the QPCR reaction with IQ Sybr Green 166 
Super Mix (Bio-Rad). Primers were designed to amplify a fragment between exon 15 167 
(forward primer: ATCCTACTGCTGCTGCACCT) and exon 17 (reverse primer 168 
ACAGCAGCTTTGCACTCAGA) of human GPAT2.  The thermal profile was 50 °C for 169 
10 min, 95 °C for 5 min, followed by 40 cycles of 95 °C for 30 s, 60 °C for 1 min and 72 170 
°C for 30 s, on a Stratagene Mx3000P apparatus.  RNA expression of the gene of 171 
interest was quantified in triplicate using the ΔCt method, and normalized to that of TBP 172 
and β-actin housekeeping genes using Qbase software. 173 
 174 
Cell proliferation, soft agar growth and wound healing assays- Cell proliferation 175 
rates were assessed by reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-176 
diphenyltetrazolium bromide) reagent [16].  Six-thousand cells were seeded in 12-well 177 
plates and cultured for 72 h.  Viability was estimated at different time points.  Briefly, 50 178 
μl of MTT stock solution (5 mg/ml in PBS, pH 7.5) was added to each well at the 179 
indicated time points and incubated for 4 h at 37°C in the darkness.  Then, 500 μl of 180 
solubilizing solution (0.04 M HCl in isopropanol) was added and incubated for 20 181 
minutes at RT.  Plates were read at 560 nm, and 640 nm for background subtraction, in 182 
a Beckman Coulter -  Multimode microplate reader DTX-880.  183 
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For soft agar assay, a base layer of 1.5 ml of the corresponding culture media 184 
containing 0.5% agarose and 10% FBS was added to 35-mm plates. After the base 185 
layer was solidified, 5000 cells  were resuspended in 1.5 ml of culture media containing 186 
0.35% agarose and 10% FBS and added to the plates.  Plates were incubated at 37°C 187 
in a humidified incubator for 14 d.  Colonies were visualized and counted under 188 
florescence microcopy in an inverted microscope (Olympus, IX71). 189 
For wound healing assay, cells were grown to confluence on 10 mm plates and 190 
wounded six times in the cell monolayer with a 200-μl standard pipette tip.  Cells were 191 
then washed twice with PBS to remove cell debris and incubated with routine 192 
conditions.  Images of the area of cell-free wounds were captured at 0, 2, 6 and 8 h. 193 
using an inverted microscope (Olympus, IX71) equipped with a digital camera 194 
(Olympus) under 100X magnification.  To quantify the migration rate of the cells, the 195 
wound width was measured at ten different regions for each wound at each time point, 196 
and the mean and standard deviation were calculated. 197 
 198 
Apoptosis assay-  Cells were seeded in triplicate on coverslips placed into 6-well 199 
plates and allowed to grow until the cell density reached 2.5 x 105 cells per well (60% 200 
confluence).  A 1 mM stock solution of staurosporin (STS) was prepared in DMSO, and 201 
added to the culture medium to give 1 µM STS final concentration.  The cultures were 202 
subsequently incubated for different time periods.  Terminal deoxynucleotidyl 203 
transferase-mediated dUTP (2´-deoxyuridine 5´-triphosphate)-digoxigenin nick end 204 
labeling (TUNEL) assay was performed on culture cells using the In Situ Cell Death 205 
Detection Kit (Roche), according to the manufacturer’s instructions.  Finally, coverslips 206 
were mounted on slides and stained with haemotoxylin.  The percentage of apoptotic 207 
cells was calculated by determining the number of TUNEL positive cells in 10 randomly 208 
selected 60X fields using an optical microscope (Nikon, E100). 209 
 210 
GPAT2 overexpression:  Human GPAT2 was stably overexpressed in MDA-MB-211 
231 cells.  To obtain stable cell lines, MDA-MB-231 cells were grown in 60-mm dishes 212 
to 90% confluence and then transfected with 5 µg of the cDNA encoding the complete 213 
open reading frame of human GPAT2 cloned in the pCMV6 vector (TrueORF, Origene) 214 
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or with the empty vector as control.  Both plasmids also contain a sequence coding for 215 
green fluorescent protein driven by an IRE translational element.  Cells were transfected 216 
using Lipofectamine 2000 and then selected with Geneticin (Life Technologies) to 217 
establish pCMV6-GPAT2 (GPAT2-overexpressing) and pCMV6 (control) cells, which 218 
were used for MTT and TUNEL assays as described above.  219 
Murine Gpat2 was transiently overexpressed in HeLa, Vero and HEK293 cells. 220 
Eight-thousand cells/well were seeded in 48MW plates and 24 h later cells were 221 
transfected with 0.6 µg/well of the cDNA encoding the complete ORF of murine Gpat2 222 
cloned into pcDNA3.1 vector (pcDNA3.1-Gpat2) or the empty pcDNA3.1 vector as 223 
previously reported [4].  Forty-eight h later, cell density was assessed by crystal violet 224 
staining [16].  GPAT2 and Gpat2 overexpression was monitored by qPCR. 225 
 226 
Immunohistochemistry- To examine the expression of GPAT2 protein in human 227 
breast cancer tissue, we performed immunohistochemistry on a tissue microarray 228 
(TMA) of human breast cancers (n= 36) or normal tissue (n=6) (Origene, CT565863).  229 
Endogenous peroxidase was inactivated by 1% H2O2 in methanol for 30 min.  The slide 230 
was then washed three times with 1X PBS and blocked with 10% normal horse serum 231 
in 1% bovine serum albumin (Sigma) in 1X PBS for 1 h.  The antigen retrieval was 232 
performed immersing the slide in 10 mM citrate buffer (pH 6) at 100ºC for 5 min.  After 233 
washing three times with PBS, the slide was incubated with rabbit anti-human GPAT2 234 
(Sigma HPA036841) polyclonal antibody (1:35) overnight at 4°C in a humidified 235 
chamber. Then, secondary HRP-conjugated anti-rabbit immunoglobulin diluted in the 236 
blocking solution (1:150; Thermo-Pierce) was added for 1 h at room temperature.  The 237 
reaction was developed with the LSAB2/HRP kit and liquid 3,3′-diaminobenzidine 238 
(Dako) according to the manufacturer's recommendations.  Slides were counter-stained 239 
with haematoxylin to visualize the nuclei and analyzed with an Olympus BX52 240 
microscope.  241 
 242 
5-aza-2'-deoxycytidine (DAC) treatment-  To determine the effect of demethylation 243 
on the expression of the GPAT2 gene, HEK293, HeLa, MCF7 and MDA-MB-231 cells 244 
were seeded at low density in six-well plates and treated with 2 μM DAC (Sigma) or 245 
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DMSO for 96 h.  After treatment, RNAs were isolated and analyzed for GPAT2 246 
expression as described above. 247 
 248 
Athymic nude mice xenografts-  Athymic female nude mice (N:NIH(S)-nu/nu/ LP , 6 249 
wk-old) were obtained from Facultad de Ciencias Veterinarias, UNLP (La Plata, 250 
Argentina).  After a one-wk acclimation period, mice were randomly divided into three 251 
groups (shRNA-GPAT2, shRNA-Scr or control; n=5 per group).  Then, 3.2 × 106 252 
shRNA-GPAT2 or shRNA-Scr cells (suspended in 200μl DMEM) were inoculated 253 
subcutaneously on the upper back of the mice; the control group received only the 254 
vehicle.  Thereafter, mice were monitored daily for tumor occurrence by visual 255 
inspection and palpation.  When detected, tumor growth was monitored twice weekly 256 
using calipers, and tumor volume was calculated using the following formula: length × 257 
width2 × 1/2.  Twelve wk after cell administration, mice were euthanized and xenograft 258 
tumors were excised and weighed.    259 
 260 
Statistical analysis- Statistical comparisons were performed with SPSS statistics 261 
17.0 software. The T-test or ANOVA, and the exact Fisher test were employed for 262 




GPAT2 is highly expressed in human testis and several cancer types-  Because 267 
GPAT2 has been proposed to be a novel CT gene and in order to validate its high 268 
expression in human testis and in cancers, we performed an in silico analysis of GPAT2 269 
mRNA expression.  First, we evaluated the gene expression profile in 36 different 270 
normal human tissues and confirmed that the highest expression of GPAT2 was in 271 
testis (p<0.01, Figure 1A).  The expression profile obtained from this analysis allowed 272 
us to classify GPAT2 expression as “testis-selective” [17].  273 
To determine out which tumor locations express high GPAT2 mRNA levels, we 274 
analyzed a compiled dataset of 1693 samples derived from 13 different cancer types 275 
(Figure 1B). According to GPAT2 expression, samples were divided into three 276 
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categories: low, moderate and high as detailed in the previous section.  Statistical 277 
analysis revealed that tumor locations with higher percentage of samples in the “high 278 
GPAT2 expression group” (p<0.01) were: melanoma (44%), lung (41%), prostate (65%), 279 
and breast tumor  (42%). On the other hand, renal (55%), colorectal (47%), 280 
hepatocellular (64%), basal cell (67%) and hematological cancers (AML, 47%; UCSD 281 
CLL, 51%) showed a significantly higher percentage of samples with low expression of 282 
GPAT2 (p<0.01).  We also evaluated GPAT2 expression profile in cancer cell lines in 283 
order to get an in vitro model of GPAT2 expressing cell line.  Fifty nine cell lines derived 284 
from 9 different cancers were analyzed.  GPAT2 showed the highest expression level in 285 
the breast cancer cell line MDA-MB-231, which is characterized as a very aggressive 286 
tumor, because it is highly proliferative and tumorigenic (Figure 1C).  This cell line was 287 
therefore chosen as our primary in vitro model to evaluate the phenotypic 288 
consequences of GPAT2 silencing.   289 
 290 
GPAT2 promotes cell proliferation, anchorage-independent growth, migration and 291 
survival of MDA-MB-231 cells-  To analyze and compare different phenotypic 292 
consequences of GPAT2 stable silencing on MDA-MB-231, we used RNA interference 293 
technology to knock down GPAT2 expression and obtained two stable cell lines: MDA-294 
MB-231 that expresses shRNA targeting GPAT2 (shRNA-GPAT2) and a control MDA-295 
MB-231 cell line expressing a scrambled shRNA (shRNA-Scr).  A 95% down-regulation 296 
of GPAT2 mRNA was obtained for shRNA-GPAT2, compared to shRNA-Scr cells 297 
(p<0.01, Figure 2A).  298 
The MTT proliferation assay was used to test changes in cell growth rate.  299 
Interestingly, the proliferation rate of the GPAT2 silenced cells was 2-fold lower 300 
compared to the scrambled cells (p<0.01, Figure 2B).  We also evaluated the 301 
anchorage-independent growth capacity, a main feature of malignant transformation, 302 
which measures the proliferation rate in a semisolid culture media.  Silencing of GPAT2 303 
markedly diminished the ability of MDA-MB-231cells to grow in a semisolid medium; the 304 
number of colonies counted at 14 days was reduced by 90% in shRNA-GPAT2 vs. 305 
shRNA-Scr cells (p<0.001, Figure 2C). 306 
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Cell migration was also diminished in the wound healing assay.  The percentage of 307 
wound closure was lower in shRNA-GPAT2 vs shRNA-Scr cells at 6 h (43.3% vs. 308 
68.7%; p<0.01), and 8 h (51.9% vs. 88.1%; p<0.01) after wound production (Figure 2D).   309 
In order to learn whether GPAT2 silencing alters sensitivity to apoptosis, we 310 
treated shRNA-GPAT2 and shRNA-Scr cells with the apoptosis inducer STS (1 µM final 311 
concentration) for 30 min and 2 h.  The percentage of apoptotic cells was determined by 312 
TUNEL assay (Figure 2E).  At 30 min of treatment, apoptosis was dramatically 313 
increased in silenced cells compared to control cells (85.4% and 6.6%, respectively; 314 
p<0.001); this effect was also evident at 2 h with 96 % and 37% mortality, respectively; 315 
p<0.01.  The vehicle DMSO did not induce apoptosis in our assay conditions.  316 
In order to check the phenotypic consequences of GPAT2 silencing in other 317 
cancerous cell line, HCT116 was chosen due to its high GPAT2 expression level 318 
(Figure 1C). GPAT2 mRNA was stably knocked-down by 70 % (Figure 3A), and 319 
consistent with MDA-MB-231 cells, shRNA-GPAT2 cell line proliferation rate was lower 320 
than shRNA- Scr cell line (Figure 3B).  321 
These results clearly showed that GPAT2 down regulation diminished cell 322 
proliferation and increased sensitivity to apoptosis of MDA-MB-231 cells.   To test 323 
whether GPAT2 overexpression evokes a reverse phenotype we obtained a stable 324 
MDA-MB-231 cell line overexpressing GPAT2 (pCMV6-GPAT2) 8.5-fold higher than the 325 
empty-vector control.  These cells proliferated 2-times faster than control cells (Figure 326 
4A and B).  STS-induced apoptosis was measured in pCMV6-GPAT2 and pCMV6 cells 327 
by TUNEL assay. When treated with 1 µM STS for 2 h, pCMV6-GPAT2 cells had a 328 
lower percentage of apoptotic cells than control cells (37% vs 44% p<0.01). After 5 h of 329 
incubation, 95% of control cells showed apoptotic traits whereas only 77% of GPAT2 330 
overexpressing cells were affected, (p<0.001, Figure 4C), showing that pCMV6-GPAT2 331 
cells were more resistant to STS-induced apoptosis.  The effect of GPAT2 expression 332 
on cell proliferation was also evident when cDNA coding for murine Gpat2 was 333 
transiently transfected in different cell lines. Cell proliferation increased 68%, 100% and 334 
48% when Gpat2 was overexpressed in HeLa, Vero and HEK293 cells respectively 335 




GPAT2 silencing inhibits MDA-MB-231 tumorigenicity in vivo- Results obtained in 338 
vitro led us to evaluate the tumorigenicity of the MDA-MB-231 shRNA-GPAT2 cells in 339 
nude mice.  While 100% (5/5) of shRNA-Scr inoculated mice developed tumors, none of 340 
the mice given shRNA-GPAT2 (0/5) generated tumor xenografts.  These results 341 
suggest that GPAT2 silencing severely inhibited the tumorigenicity of MDA-MB-231 342 
cells. 343 
 344 
GPAT2 is highly expressed in undifferentiated breast carcinomas-  We showed that 345 
GPAT2 expression is required for the high rate of proliferation, anchorage independent 346 
growth, tumorigenicity, and survival of MDA-MB-231 cells.  To analyze GPAT2 347 
expression at the protein level in human breast adenocarcinomas, we performed 348 
immunohistochemistry (using an anti-GPAT2 antibody previously validated in our lab 349 
[4]) on a commercial breast tissue microarray.  GPAT2 was not detected in any of the 350 
normal samples (n=6), but its frequency in carcinomas (n=35) was 37% (Figure 5A and 351 
B).  Similar to its subcellular localization in normal testicular germ cells, GPAT2 showed 352 
immunoreactivity in the cytoplasm of cancerous cells (Figure 5A, middle panel).  When 353 
the histopathological variables were analyzed, a significant positive association with the 354 
histological grade was obtained.  Only 11% of Grade I/II tumor samples were positive 355 
for GPAT2 protein expression, compared to 55% for Grade III samples (p<0.05) (Figure 356 
5C). 357 
 358 
GPAT2 expression is upregulated by DAC treatment-  Epigenetic regulation is a 359 
hallmark of cancer testis gene expression [18].  To assess whether GPAT2 expression 360 
is regulated by DNA methylation, we treated HEK293, HeLa, MCF7 and MDA-MB-231 361 
cell lines with the methyltransferase inhibitor DAC at 2 µM for 96 h or with DMSO as a 362 
control.  The expression of GPAT2 was low in HEK293, HeLa and MCF7 cells 363 
compared to MDA-MB-231 cells (Figure 6A).  DAC treatment was able to significantly 364 
increase GPAT2 expression in HEK293, HeLa and MCF7 cells, but had no effect on 365 
MDA-MB-231 cells (Figure 6B).  This result strongly suggests that GPAT2 expression is 366 




In silico co-expression analysis indicates that GPAT2 would be associated with 369 
piRNA metabolism and cell cycle control pathways- Based on our experimental results 370 
and to identify the functional role of GPAT2, we performed a co-expression analysis in 371 
mouse and human testis.  The top 300 best correlated genes (p<0.001) were selected 372 
for functional analysis.  A visual summary of no redundant gene ontology terms was 373 
obtained by using DAVID and REVIGO bioinformatics tools.  Remarkably, similar gene 374 
ontology terms were identified in mouse and human analyses (Figure 7).  In both 375 
species, two clusters involving gene ontology terms connections were evident.  One of 376 
these clusters, contained general terms like sexual reproduction and gamete 377 
generation, and included cell cycle-related gene ontology terms, like cell division, cell 378 
proliferation, cell cycle process, regulation of cell cycle and chromosome segregation.  379 
The other cluster was related to DNA metabolism including gene ontology terms like 380 
DNA methylation, regulation of gene expression, epigenetic, RNA biosynthesis, DNA 381 
modification and piRNA metabolism.  Among the co-expressed genes with human 382 




The main finding of this study is that GPAT2 does not behave as a “classical” GPAT 387 
and its expression is linked to malignancy rather than to glycerolipid synthesis.  We 388 
have previously reported in mice and rats that GPAT2 expression and activity is 389 
unrelated to the other three isoforms [4].   390 
Human GPAT2 has been proposed as a novel CT gene candidate [6] based only on 391 
the fact that GPAT2 mRNA expression profile was selective to the testis and to 392 
myeloma cells.  In order to validate this hypothesis, we have taken both in silico and 393 
experimental approaches to confirm that GPAT2 meets the criteria of a CT gene.  We 394 
explored GPAT2 distribution in different cancer tissues, we detected GPAT2 expression 395 
at protein level in cancer cells and we obtained evidence that GPAT2 expression is 396 
epigenetically regulated.  397 
One of the main features of CT genes is that they are expressed not only in testis 398 
but also in tumors.  In this sense, tumors have been classified in high, moderate or low 399 
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CT gene expressers [19].  Using data available in public databases, we analyzed the 400 
GPAT2 expression profile in human tumor samples and found that in each tumor 401 
location only a fraction showed high GPAT2 expression levels. The locations in which 402 
there was a statistically higher proportion of samples with “high expression” were lung, 403 
melanoma, breast, and prostate cancer, whereas “low expression” was most frequent 404 
in renal, colorectal, and hepatocellular cancers and in hematopoietic malignancies.  This 405 
expression pattern in different tumors is consistent with the distribution of other CT 406 
genes in human cancers [19].  Although the number of CT genes identified has been 407 
increasing, knowledge of the expression pattern at the protein level is still limited.  In 408 
this study, we explored GPAT2 protein expression in breast carcinoma tissues, and 409 
found that 36% of breast tumors express this protein.  This frequency is relatively high 410 
compared to reported frequencies for other CT genes in breast cancer [19].  411 
Additionally, when histopathological variables were analyzed, GPAT2 showed a positive 412 
association with the histological grade, which is also characteristic of CT genes, since 413 
they are preferentially expressed in high grade breast cancers [8,20].  414 
Another hallmark of CT genes is epigenetic regulation.  CT genes have methylated 415 
promoters in normal non-expressing somatic tissues and are activated by demethylation 416 
during spermatogenesis and carcinogenesis [18,20].  DAC treatment of human cell lines 417 
expressing GPAT2 at very low levels evoked a very strong induction of gene 418 
expression, whereas the same treatment had no effect on MDA-MB-231 cells, which 419 
normally express GPAT2.  These results allowed us to conclude that 420 
methylation/demethylation is a mechanism governing GPAT2 expression. 421 
One key question about CT genes is whether their expression contributes to the 422 
tumor phenotype.  To address this, we stably knocked-down GPAT2 in MDA-MB-231 423 
cells.  Gene abrogation dramatically decreased cell proliferation, anchorage 424 
independent growth and migration of MDA-MB-231 cells, features that are all related to 425 
tumor progression.  GPAT2 silencing also diminished cell proliferation of HCT116 cells 426 
and both murine and human GPAT2 overexpression increased cell proliferation. These 427 
results agree with experiments reporting either siRNA-mediated silencing or 428 
overexpression of specific CT genes, which demonstrate causality between CT gene 429 
expression and growth phenotype [21–25].  The dramatic reduction of the MDA-MB-231 430 
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tumor phenotype by GPAT2 silencing was also evident in vivo, because knocked down 431 
cells were unable to generate tumor xenografts in nude mice.  The contribution of 432 
GPAT2 to malignancy appears to be not only restricted to an increased cell proliferation, 433 
because GPAT2 silenced cells were more sensitive to STS induced apoptosis and 434 
GPAT2 overexpressing cells were more resistant to STS induced apoptosis.  435 
Our results, as well as those reported from other groups, support the idea that 436 
ectopic CT gene expression in somatic cells promotes tumorigenesis.  The mechanisms 437 
by which each CT gene contributes to a tumor phenotype are poorly understood but 438 
revealing CT gene function in spermatogenesis could provide clearer insights into how 439 
CT genes act in cancer.  For this reason, we performed a co-expression analysis for 440 
GPAT2 in mouse and human testis, the tissue in which GPAT2 exerts its physiological 441 
role.  Two main clusters of ontological terms in both species were found.  One of these 442 
clusters was associated with the regulation of gene expression by epigenetic 443 
mechanisms, RNA biosynthesis and piRNA metabolism, consistent with a report that 444 
GPAT2 plays a critical role in piRNA biogenesis [5].  piRNAs are small non-coding 445 
RNAs synthesized in germ cells, whose accepted function is to use DNA methylation to 446 
repress the expression in germ cells of deleterious retrotransposons [26].  The 447 
relationship between piRNA metabolism and cancer has been considered.  In 448 
Drosophila ectopic expression of piRNA pathway genes are responsible for the 449 
development of brain tumors [27] and specific piRNAs are aberrantly overexpressed in 450 
gastric, colon, lung and breast cancer tissues [28].  However, the mechanisms of 451 
piRNAs involvement in tumorigenesis are yet to be determined.  The second cluster 452 
showed ontological terms associated with cell cycle, such as M phase, chromosome 453 
segregation, centromere complex assembly and cell proliferation, suggesting a role for 454 
GPAT2 in the control of cell cycle, perhaps through its participation in chromosome 455 
segregation.  Whether all these terms are associated with piRNA metabolism or if they 456 
reveal an independent function for GPAT2 must be determined, but a link between 457 
piRNA metabolism and mitosis was recently described [29].   458 
In summary, our co-expression analysis in mouse and human testis confirm the role 459 
of GPAT2 in piRNA metabolism and suggest an emerging role for GPAT2 in the control 460 
of cell cycle, probably through its participation in chromosome segregation.   461 
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Our present data linking GPAT2 to tumorigenesis open the possibility of considering 462 
GPAT2 as a potential target for treatment of highly aggressive cancers. 463 
 464 
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 569 
FIGURE LEGENDS 570 
 571 
FIGURE 1: In silico analysis of GPAT2 mRNA expression profile.  A) In silico analysis of 572 
GPAT2 expression profile across human normal tissues.  B) GPAT2 mRNA expression 573 
across different tumor localizations was assessed with a bioinformatics approach, and 574 
expression level was classified into low, moderate and high. The percentage of cases in 575 
each category (low: light gray, moderate: dark gray, high: black) is displayed in the 576 
graph ** p< 0.01.  C) GPAT2 expression profile across human cancer cell lines. 577 
 578 
FIGURE 2: Phenotypic consequences of GPAT2 knock down in MDA-MB-231 cells A) 579 
Total RNA was extracted from the MDA-MB-231 parent cell line, shRNA-Scr and 580 
shRNA-GPAT2 cells, subjected to cDNA synthesis and amplified by quantitative RT-581 
PCR using primers for human GPAT2 gene, normalizing its expression level to that of 582 
TBP and β-actin housekeeping genes ** p< 0.01.  B) shRNA-Scr and shRNA-GPAT2 583 
cells were seeded at 10,000 cells/well on MW12 plates and incubated for 24, 48, and 72 584 
h before estimating the cell proliferation rate by MTT proliferation assay * p< 0.05.  C) 585 
5,000 cells from shRNA-Scr and shRNA-GPAT2 cells were seeded on 35-mm DMEM-586 
agar plates and the number of colonies was quantified by fluorescent microscope after 587 
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14 d incubation under normal culture conditions *** p< 0.001.  D) shRNA-Scr and 588 
shRNA-GPAT2 cells were grown to confluence on 10 mm plates and the cell monolayer 589 
was wounded six times.  The wound width was measured at 0, 2, 6 and 8 h under 100X 590 
magnification and the percentage of wound closure was calculated * p< 0.05.  E)  591 
shRNA-Scr and shRNA-GPAT2 cells were treated with apoptosis inducer staurosporine 592 
for 30 min or 2 h and the percentage of apoptotic cells was determined by counting the 593 
number of apoptotic and non-apoptotic cells using TUNEL assay and haematoxylin 594 
staining ** p< 0.01; *** p< 0.001.      595 
 596 
FIGURE 3: GPAT2 knock down in HCT116 cells A) Total RNA was extracted from the 597 
HCT116 parent cell line, shRNA-Scr and shRNA-GPAT2 cells, subjected to cDNA 598 
synthesis and amplified by quantitative RT-PCR using primers for human GPAT2 gene, 599 
normalizing its expression level to that of TBP and β-actin housekeeping genes ** p< 600 
0.01.  B) shRNA-Scr and shRNA-GPAT2 cells were seeded at 5000 cells/well on MW12 601 
plates and incubated for 24, 48, 72  and 96 h before estimating the cell proliferation rate 602 
by MTT proliferation assay *** p< 0.001. 603 
 604 
FIGURE 4: Phenotipic consequences of human and murine GPAT2 overexpression. A) 605 
Total RNA from pCMV6 and pCMV6-GPAT2 cells  was extracted, subjected to cDNA 606 
synthesis and amplified by quantitative RT-PCR using primers for human GPAT2 gene, 607 
normalizing its expression level to that of TBP and β-actin housekeeping genes *** 608 
p<0.001.  B) pCMV6 and pCMV6-GPAT2 cells were seeded at 10,000 cells/well on 609 
MW12 plates  and incubated for 24, and 48 h before estimating the cell proliferation rate 610 
by MTT proliferation assay *** p< 0.001.  C) pCMV6 and pCMV6-GPAT2 cells were 611 
seeded in coverslips and 24 h later apoptosis was induced by 1µM staurosporine 612 
treatment for 2 and 5 h.  The percentage of apoptotic cells was determined by counting 613 
the number of apoptotic and non-apoptotic cells using TUNEL assay and haematoxylin 614 
staining ** p< 0.01; *** p< 0.001.  D) pcDNA3.1 (empty vector) and the cDNA coding for 615 
mouse Gpat2 cloned in pcDNA3.1 (pcDNA3.1-Gpat2) were transiently transfected in 616 
HeLa, Vero and HEK293 cells.  Cell density was estimated 48 h post-transfection by 617 




FIGURE 5: GPAT2 protein expression in human breast carcinomas.  GPAT2 protein 620 
expression in human breast tissues was assayed on a tissue microarray (TMA) by 621 
immunohistochemistry. A) Representative samples of normal breast (left panel), breast 622 
adenocarcinoma positive for GPAT2 stainning (GPAT2 (+)) (middle panel) and breast 623 
adenocarcinoma negative for GPAT2 staining (GPAT2(-)) (right panel) are displayed. 624 
GPAT2 expression was detected by peroxidase reaction (brown signal, arrows) and 625 
nuclei were counterstained with haematoxilin (blue stain).  Magnification: 200X, 600X 626 
and 1000X. Statistical analysis of GPAT2 protein expression on the TMA: B) frequency 627 
of GPAT2 expression between normal breast and breast adenocarcinoma (carcinoma) 628 
and C) frequency of GPAT2 expression in adenocarcinoma (carcinoma) samples 629 
according to their histological grade (Nottingham scale). 630 
 631 
FIGURE 6: Effect of DAC treatment on mRNA GPAT2 expression in human cell lines.  632 
A) Relative mRNA expression of GPAT2 in human cell lines was assayed by 633 
quantitative RT-PCR.  B) MCF7, HeLa, HEK-293 and MDA-MB-231 cells were treated 634 
with the methyltransferase inhibitor 5-aza-2’-deoxycitidyne 2 µM for 96 h (DAC) or with 635 
DMSO (control), and the mRNA relative expression of GPAT2 gene was assessed by 636 
quantitative RT-PCR. ** p< 0.01. 637 
 638 
FIGURE 7: Gene ontology classification of genes co-expressed with GPAT2 in mouse 639 
and human testis.  Scatterplot graph of the top 300 GPAT2 co-expressed genes 640 
showing the representative functional clusters according to gene ontology terms with a 641 
statistical significance of p<0.01, in a two dimensional space related to gene ontology 642 
terms' semantic similarities.  Bubble color indicates the p-value of gene ontology terms 643 
(expressed as Log10 p-value), where blue and green bubbles are gene ontology terms 644 
with more significant p-values than the orange and red bubbles.  Bubble size indicates 645 
the frequency of the gene ontology term in the underlying gene ontology database. 646 
 647 
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